Glucocorticoids (GCs) have powerful anti-inflammatory and immunomodulatory effects and are useful for treating many rheumatic diseases.
Glucocorticoids work by inhibiting leukocyte access to infl amed tissues, interfering with the function of cells involved in the infl ammatory process, and suppressing the production of humoral factors such as cytokines and prostaglandins involved in immune infl ammatory processes.
Glucocorticoids accomplish their effects by several mechanisms, including altering synthesis of proteins, releasing proteins from intracellular protein complexes that include GC receptors, and changing the properties of biological membranes.
Initial GC dosage should be determined by the type and severity of the disease manifestation under treatment.
■ Because of signifi cant toxicity associated with long-term GC use, doses of <7.5 mg daily are recommended only if required to control symptoms.
KeywordsRheumatic Disease Early Rheumatoid Arthritis Nongenomic Effect Previous Gestational Diabetes Mellitus Prednisolone Equivalent
Unable to display preview. Download preview PDF.
- 4.Buttgereit F, Burmester GR, Lipworth BJ. Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet 2005;375:801–803.Google Scholar
- 7.Goulding NJ, Flower RJ. Glucocorticoid biology-a molecular maze and clinical challenge. In: Goulding NJ, Flower RJ, eds. Milestones in drug therapy: glucocorticoids. Basel: Birkhäuser Verlag; 2001:5.Google Scholar
- 13.Van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical effi cacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002;136:1–12.PubMedGoogle Scholar
- 15.Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafstrom I. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005;52:3360–3370.PubMedCrossRefGoogle Scholar